The FDA has added new warnings to GLP-1 medications such as Ozempic, Wegovy, and Mounjaro about pulmonary aspiration risk during general anesthesia or deep sedation. Reports indicate some patients on ...
On March 3, 2026, FDA announced it had issued 30 warning letters to telehealth companies marketing compounded GLP‑1 products whose promotion of compounded GLP‑1s, in FDA’s view, implies equivalence to ...
On March 3, 2026, U.S. Food & Drug Administration (FDA) sent 30 warning letters to telehealth companies that market compounded GLP‑1 products. These letters highlight FDA’s current enforcement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results